寡复发前列腺癌的转移导向治疗与标准治疗:单中心经验
在仅淋巴结复发患者中,sLND和EBRT较ADT显著改善影像学复发、二线系统治疗及去势抵抗前列腺癌(CRPCa)无生存,但两者间无差异;骨转移患者中MDT未见生存获益。
要点
- 仅淋巴结复发患者中,sLND和EBRT较ADT改善影像学复发、二线治疗及CRPCa无生存。
- sLND与EBRT在肿瘤学结局上无显著差异。
- 骨转移患者中,MDT较ADT无生存获益。
核心结论
- 在仅淋巴结复发的寡转移前列腺癌患者中,sLND和EBRT较ADT与更好的影像学复发、二线系统治疗及CRPCa无生存相关。
- sLND与EBRT之间生存结局无差异。
- 骨转移患者中,MDT较ADT无生存获益。
主要发现
- 仅淋巴结复发患者中,sLND(HR 0.56,95%CI 0.33-0.94)和EBRT(HR 0.46,95%CI 0.25-0.85)较ADT与更好的影像学复发相关。
- sLND(HR 0.25,95%CI 0.13-0.50)和EBRT(HR 0.41,95%CI 0.19-0.87)较ADT与更长的二线系统治疗时间相关。
- CRPCa状态结果类似,sLND与EBRT之间肿瘤学结局相似。
- 骨转移患者中,MDT较ADT无生存获益。
临床怎么用
- 对于仅淋巴结复发的寡复发前列腺癌,可考虑sLND或EBRT作为ADT的替代方案。
- 骨转移患者中,MDT不应常规用于改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment for oligorecurrent prostate cancer (PCa) is a matter of debate. We aimed to assess oncologic outcomes of patients treated with metastasis-directed therapy (MDT) vs. androgen deprivation therapy (ADT) for oligorecurrent PCa. METHODS: We analyzed data from patients with oligorecurrent PCa treated with ADT (n = 121), salvage lymph node dissection (sLND) (n = 191) or external beam RT (EBRT) (n = 178). Radiological recurrence (RAR) was defined as a positive positron emission tomography imaging after MDT or ADT. Second-line systemic therapies (SST) were defined as any systemic therapy administered for progression. Oncologic outcomes were evaluated separately for patients with node-only or bone metastases. Kaplan-Meier method was used to assess time to RAR, SST, and cancer-specific mortality (CSM). Predictors of RAR, SST, and castration-resistant PCa (CRPCa) were assessed with Cox regression analyses. RESULTS: Overall, 74 (22.6%), 63 (19.2%), and 191 (58.2%) patients were treated with ADT, EBRT, and sLND for lymph node-only recurrence. Both sLND (HR 0.56, 95% CI 0.33-0.94) and EBRT (HR 0.46, 95% CI 0.25-0.85) were associated with better RAR than ADT. Similarly, sLND (HR 0.25, 95% CI 0.13-0.50) and EBRT (HR 0.41, 95% CI 0.19-0.87) were associated with longer SST, as compared with ADT. Similar results were found for CRPCa status. Oncologic outcomes were similar between sLND and EBRT. MDT was not associated with survival benefit in patients with bone metastases as compared with ADT. CONCLUSIONS: sLND and EBRT were associated with better RAR, SST, and CRPCa-free survival as compared with ADT in patients with oligometastatic PCa nodal recurrence. No difference in survival outcomes was observed between sLND and EBRT. MDT was not associated with survival benefit in patients with bone metastases, as compared with ADT.
引用
- Boeri L, Sharma V, Kwon E, et al. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2020. PMID: 33268854. doi:10.1038/s41391-020-00307-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。